An interferon-gamma ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies.

Abstract	Eight patients with paraneoplastic cerebellar degeneration (PCD) and anti-Yo antibodies were investigated to determine whether there is any association between cytotoxic T lymphocyte (CTL) responses reactive with two previously defined Yo-derived, HLA-A2.1 restricted epitopes (cdr2-1 and cdr2-2) and the presence of tumour-infiltrating CD8+ CTLs. cdr2-1 and cdr2-2-specific CTL responses could not be detected in 5 HLA-A2.1(+) patients in an ex vivo interferon-gamma ELISPOT assay and only 2/9 tumour sections contained CD8(+) intratumoural lymphocytes suggesting a very limited role for CTL-mediated tumour immunity in this patient group, all of whom had evidence of widespread malignancy at the time of diagnosis and/or death.
Authors	I J Sutton, J Steele, C O Savage, J B Winer, L S Young
Journal	Journal of neuroimmunology (J Neuroimmunol) Vol. 150 Issue 1-2 Pg. 98-106 (May 2004) ISSN: 0165-5728 [Print] Netherlands
PMID	15081253 (Publication Type: Journal Article)
Chemical References	Antibodies, Neoplasm CDR2 protein, human DNA-Binding Proteins Epitopes, T-Lymphocyte HLA-A2 Antigen Neoplasm Proteins Nerve Tissue Proteins Protein Isoforms Interferon-gamma
Topics	Antibodies, Neoplasm (blood) Breast Neoplasms (immunology) Cerebellar Neoplasms (immunology) Cytotoxicity Tests, Immunologic DNA-Binding Proteins (immunology) Enzyme-Linked Immunosorbent Assay (methods) Epitopes, T-Lymphocyte (immunology) Female HLA-A2 Antigen (immunology) Humans Immunohistochemistry Interferon-gamma (analysis, metabolism) Lymphocyte Count Lymphocytes, Tumor-Infiltrating (chemistry, immunology, pathology) Neoplasm Proteins (immunology) Nerve Tissue Proteins (immunology) Ovarian Neoplasms (immunology) Paraneoplastic Cerebellar Degeneration (diagnosis, immunology, pathology) Protein Isoforms (immunology) Staining and Labeling T-Lymphocytes, Cytotoxic (immunology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!